false
Catalog
The Lead Episode 20: A Discussion of (RAPID): A Mu ...
The Lead Episode 20 Speaker Information
The Lead Episode 20 Speaker Information
Back to course
Pdf Summary
The article titled "A Discussion of Self-Administered Intranasal Etripamil Using a Symptom-Promoted, Repeat-Dose Regimen for Atrioventricular-Modal-Dependent Supraventricular Tachycardia (RAPID): A Multicentre, Randomised Trial" was the topic of discussion hosted by Dr. William H. Sauer.<br /><br />The authors of the article are Bruce S Stambler, A John Camm, Marco Alings, Paul Dorian, Hein Heidbuchel, Jaco Houtgraaf, Peter R Kowey, Jose L Merino, Blandine Mondésert, Jonathan P Piccini, Sean D Pokorney, Philip T Sager, Atul Verma, J Marcus Wharton, David B Bharucha, Francis Plat, Silvia Shardonofsky, Michael Chen, and James E Ip.<br /><br />The discussion involved Dr. Sunil Kapur and Dr. David Chiang from Brigham and Women's Hospital. The article focuses on self-administered intranasal etripamil, a drug used for the treatment of atrioventricular-modular-dependent supraventricular tachycardia (SVT).<br /><br />SVT is a rapid heart rate condition that starts in the atria or atrioventricular node. The RAPID trial investigated the efficacy and safety of intranasal etripamil as a self-administered treatment option for SVT.<br /><br />The study involved a randomized, double-blind, placebo-controlled trial at multiple centers. The participants self-administered the drug when experiencing SVT symptoms. The primary endpoint was the conversion to normal sinus rhythm within 30 minutes of drug administration.<br /><br />The discussion provided insights into the mechanism of action of intranasal etripamil, the selection criteria for patients, adverse effects, and future directions in SVT treatment.<br /><br />The authors and contributors disclosed their financial relationships with various companies, including those related to the topic of discussion.<br /><br />Overall, this discussion shed light on the potential of self-administered intranasal etripamil as a convenient and effective treatment option for patients with atrioventricular-modular-dependent SVT.
Keywords
Self-administered intranasal etripamil
Symptom-promoted repeat-dose regimen
Atrioventricular-modal-dependent supraventricular tachycardia
RAPID trial
Multicentre randomized trial
Dr. William H. Sauer
Bruce S Stambler
A John Camm
Mechanism of action
SVT treatment
Heart Rhythm Society
1325 G Street NW, Suite 500
Washington, DC 20005
P: 202-464-3400 F: 202-464-3401
E: questions@heartrhythm365.org
© Heart Rhythm Society
Privacy Policy
|
Cookie Declaration
|
Linking Policy
|
Patient Education Disclaimer
|
State Nonprofit Disclosures
|
FAQ
×
Please select your language
1
English